SCHEMBL7521044

SCHEMBL7521044

Cc1cccc(NC(=O)NC2=CC(=O)OC2)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ATM Q13315 1/20 0.44
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
NTRK1 P04629 1/20 0.42
TSHR P16473 2/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
HTT P42858 1/20 0.42
DDX3X O00571 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7521744 0.89 RAB9A (0.50) GAANPC1RAB9AMAPTMEN1
SCHEMBL7522546 0.87 SMN1; SMN2 (0.53) MAPTKMT2AALDH1A1HPGDTSHR
SCHEMBL29581522 0.79 GAA (0.70) GAANPC1RAB9AMAPTMEN1
SCHEMBL15093660 0.79 GAA (0.70) GAANPC1RAB9AMAPTMEN1
SCHEMBL7519777 0.78 MEN1 (0.54) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7519218 0.78 TP53 (0.48) GAANPC1RAB9AMAPTMEN1
SCHEMBL7518729 0.78 HTT (0.50) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL7522955 0.78 KDM4E (0.55) GAANPC1RAB9AMAPTMEN1
SCHEMBL7525664 0.78 NPC1 (0.60) GAANPC1RAB9AMAPTMEN1
SCHEMBL7520047 0.78 HTT (0.53) GAANPC1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents ROCHE DIAGNOSTICS GMBH 2002-05-16 US disclosed
US-6333346-B1 AMINOFURANONEUREAS OR THIOUREAS 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 2001-12-25 US disclosed
EP-1009747-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS Roche Diagnostics GmbH (DE) 2000-06-21 EP disclosed
WO-1999012917-A1 UREIDO AND THIOUREIDO DERIVATIVES OF 4-AMINO-2(5H)-FURANONES AND 4-AMINO-2(5H)-THIOPHENONES AS ANTITUMOR AGENTS ROCHE DIAGNOSTICS GMBH (DE) 1999-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058694-A1 Ureido and thioureido derivatives of 4-amino-2(5H)-furanones and 4-amino-2(5H)-thiophenones as antitumor agents UTS2R, SRD5A2, SRD5A1 GAA 3891/4885NPC1 4118/4885RAB9A 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.